The role of ACKR3 in breast, lung, and brain cancer

Maria Neves, Amos Fumagalli, Jelle van den Bor, Philippe Marin, Martine J. Smit, Federico Mayor*

*Corresponding author for this work

Research output: Contribution to JournalArticleAcademicpeer-review

10 Downloads (Pure)


Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts.

Original languageEnglish
Pages (from-to)819-825
Number of pages7
JournalMolecular pharmacology
Issue number6
Publication statusPublished - 1 Dec 2019


This work was supported by the European Union H2020-MSCA Program [Grant Agreement 64183], ONCORNET to P.M., M.J.S., and F.M.; Ministerio de Economía, Industria y Competitividad of Spain [Grant SAF2017-84125-R] to F.M.; CIBERCV-Instituto de Salud Carlos III, Spain [Grant CB16/11/00278] to F.M.; cofunded with European FEDER contribution, Comunidad de Madrid [B2017/BMD-3671-INFLAMUNE] to F.M.; Fundación Ramón Areces to F.M.; Portuguese Foundation for Science and Technology [Grant SFRH/BD/136574/ 2018] to M.N.; Netherlands Organization for Scientific Research NWO: Vici [Grant 016.140.657] to M.J.S.; and grants from CNRS, INSERM, Université de Montpellier and Fondation pour la Recherche Médicale (FRM) to P.M. 1A.F. and J.v.d.B. contributed equally to this work.

FundersFunder number
CIBERCV-Instituto de Salud Carlos IIICB16/11/00278
European Union H2020-MSCA Program64183
Fundación Ramón Areces
Horizon 2020 Framework Programme641833
Comunidad de MadridB2017/BMD-3671-INFLAMUNE
Institut national de la santé et de la recherche médicale
Fundação para a Ciência e a TecnologiaSFRH/BD/136574/ 2018
Fondation pour la Recherche Médicale
Federación Española de Enfermedades Raras
Nederlandse Organisatie voor Wetenschappelijk Onderzoek016.140.657
Centre National de la Recherche Scientifique
Université de Montpellier
Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de EspañaSAF2017-84125-R


    Dive into the research topics of 'The role of ACKR3 in breast, lung, and brain cancer'. Together they form a unique fingerprint.

    Cite this